Silencing platelet‑derived growth factor receptor‑β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo

Hong,Ji‑Dong; Wang,Xia; Peng,Yu‑Ping; Peng,Jiang‑Hua; Wang,Jun; Dong,Ye‑Ping; He,Dan; Peng,Zhen‑Zi; Tu,Qing‑Song; Sheng,Liang‑Fang; Zhong,Mei‑Zuo; Duan,Chao‑Jun

doi:10.3892/ol.2017.6143

Silencing platelet‑derived growth factor receptor‑β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo

Authors:
- Ji‑Dong Hong
- Xia Wang
- Yu‑Ping Peng
- Jiang‑Hua Peng
- Jun Wang
- Ye‑Ping Dong
- Dan He
- Zhen‑Zi Peng
- Qing‑Song Tu
- Liang‑Fang Sheng
- Mei‑Zuo Zhong
- Chao‑Jun Duan
View Affiliations

Affiliations: Department of Radiation Oncology, The Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Institute of Medical Sciences, The Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 10, 2017 https://doi.org/10.3892/ol.2017.6143
Pages: 329-336

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platelet-derived growth factor receptor (PDGFR)‑β is an important tyrosine kinase and its downregulation has been reported to alter the radiosensitivity of glioma cells, although the underlying mechanism is unclear. In order to investigate the effect of PDGFR‑β on the radiosensitivity of glioblastoma, the present study transfected C6 glioma cells with a PDGFR‑β‑specific small interfering (si)RNA expression plasmid, and downregulation of the expression of PDGFR‑β in C6 glioma cells was confirmed by western blotting and immunohistochemical analysis. Clone formation assays and xenograft growth curves demonstrated that PDGFR‑β‑siRNA enhanced the radiosensitivity of C6 glioma cells in vitro and in vivo. Furthermore, MTT and xenograft growth curves demonstrated that PDGFR‑β‑siRNA inhibited the proliferation of C6 glioma cells in vitro and in vivo, and terminal deoxynucleotidyl transferase dUTP nick end‑labeling and immunohistochemical analyses demonstrated that PDGFR‑β‑siRNA induced apoptosis and inhibited the expression of Ki‑67, cyclin B1 and vascular endothelial growth factor in C6 glioma cell xenografts. Taken together, these results suggested that PDGFR‑β may be used as a target for the radiosensitization of glioblastoma.

View Figures

View References

1	Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15 Suppl 2:ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study, : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, Sakata K, Sasaki Y, Matsutani M and Akanuma A: High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 40:1141–1149. 1998. View Article : Google Scholar : PubMed/NCBI
5	Kohler N and Lipton A: Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res. 87:297–301. 1974. View Article : Google Scholar : PubMed/NCBI
6	Ross R, Glomset J, Kariya B and Harker L: A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 71:pp. 1207–1210. 1974; View Article : Google Scholar : PubMed/NCBI
7	Heldin CH, Westermark B and Wasteson A: Platelet-derived growth factor: Purification and partial characterization. Proc Natl Acad Sci USA. 76:pp. 3722–3726. 1979; View Article : Google Scholar : PubMed/NCBI
8	Hermansson M, Nistér M, Betsholtz C, Heldin CH, Westermark B and Funa K: Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci USA. 85:pp. 7748–7752. 1988; View Article : Google Scholar : PubMed/NCBI
9	Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM and Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest. 86:131–140. 1990. View Article : Google Scholar : PubMed/NCBI
10	Plate KH, Breier G, Farrell CL and Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest. 67:529–534. 1992.PubMed/NCBI
11	Chen D, Li Y, Mei Y, Geng W, Yang J, Hong Q, Feng Z, Cai G, Zhu H, Shi S, et al: miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell Mol Life Sci. 71:4027–4042. 2014. View Article : Google Scholar : PubMed/NCBI
12	Nazarenko I, Hede SM, He X, Hedrén A, Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N and Yang B: Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. Basic Clin Pharmacol Toxicol. 104:241–252. 2009. View Article : Google Scholar : PubMed/NCBI
14	Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K and Tofilon PJ: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63:7377–7383. 2003.PubMed/NCBI
15	Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, van Etten RA, et al: Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis. 34:181–185. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A and Nano R: Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res. 29:4575–4578. 2009.PubMed/NCBI
17	Savage DG and Antman KH: Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 346:683–693. 2002. View Article : Google Scholar : PubMed/NCBI
18	Chen SW, Zhang XR, Wang CZ, Chen WZ, Xie WF and Chen YX: RNA interference targeting the platelet-derived growth factor receptor beta subunit ameliorates experimental hepatic fibrosis in rats. Liver Int. 2008. View Article : Google Scholar
19	Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE II, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, et al: Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 118:4759–67. 2012. View Article : Google Scholar : PubMed/NCBI
20	Biade S, Stobbe CC and Chapman JD: The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res. 147:416–421. 1997. View Article : Google Scholar : PubMed/NCBI
21	Chen H, Huang Q, Dong J, Zhai DZ, Wang AD and Lan Q: Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer. 8:292008. View Article : Google Scholar : PubMed/NCBI
22	He J, Li J, Ye C, Zhou L, Zhu J, Wang J, Mizota A, Furusawa Y and Zhou G: Cell cycle suspension: A novel process lurking in G2 arrest. Cell Cycle. 10:1468–1476. 2011. View Article : Google Scholar : PubMed/NCBI
23	Maity A, Hwang A, Janss A, Phillips P, McKenna WG and Muschel RJ: Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene. 13:1647–1657. 1996.PubMed/NCBI
24	Silva MF, Khokhar AR, Qureshi MZ and Farooqi AA: Ionizing radiations induce apoptosis in TRAIL resistant cancer cells: in vivo and in vitro analysis. Asian Pac J Cancer Prev. 15:1905–1907. 2014. View Article : Google Scholar : PubMed/NCBI
25	Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T and Matsumura A: Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol. 33:107–116. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lafuente JV, Adán B, Alkiza K, Garibi JM, Rossi M and Cruz-Sánchez FF: Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci. 13:177–185. 1999. View Article : Google Scholar : PubMed/NCBI
27	Fenton BM, Paoni SF and Ding I: Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. 64:5712–5719. 2004. View Article : Google Scholar : PubMed/NCBI
28	Shannon AM and Williams KJ: Antiangiogenics and radiotherapy. J Pharm Pharmacol. 60:1029–1036. 2008. View Article : Google Scholar : PubMed/NCBI
29	Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
30	Cohen-Jonathan Moyal E: Angiogenic inhibitors and radiotherapy: From the concept to the clinical trial. Cancer Radiother. 13:562–567. 2009.(In French). PubMed/NCBI
31	Raymond E: PDGFR inhibition in brain tumours-oft expectation fails where most it promises. Eur J Cancer. 45:2236–2238. 2009. View Article : Google Scholar : PubMed/NCBI
32	Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW and Weichselbaum RR: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
33	Omuro AM: Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs. 9:1287–1295. 2008.PubMed/NCBI